摘要
骨折危险因子评估（FRAX）是世界卫生组织最新推出的预测骨折危险的评估工具。根据FRAX，低骨量和10年内髋骨骨折≥3％或骨质疏松引起的主要骨折≥20％的患者，应及时进行药物干预。其作为一种在全球大量荟萃分析基础上建立的网络评估工具，易于获取，并能简便有效的帮助临床医生判断出需要药物治疗的患者。然而，FRAX也受某些因素的限制，如没有考虑跌倒等骨折独立危险因子、没有重视剂量一效应关系、不能对已经接受治疗的患者进行评估、不能监测治疗效果等。目前FRAX不能代替已有的临床危险评估方法，还需进一步完善。
Fracture risk factor assessment （FRAX） is the latest assessment tool for fracture risk which is recommended by World Health Organization.According to it,patients with low bone density and hip fracture of ≥ 3% or a≥ 20% ten-year risk of a major osteoporosis-related fracture should be treated with drug timely.FRAX is an assessment model which is based on a series of meta-analysis around the world, as a network tool, it is easy to obtain and can help physicians to identify the patient who need a treatment effectively. However, FRAX is also limited by some factors, it does not take into account some independent risk factors for fracture such as falls and it does not pay attention to dosage-effect relationships as well.FRAX may only be used in untreated patients and it can not monitor the effect of treatment and so on.At present, FRAX can not take place of the existing clinical assessment methods, it still need to be perfected further.
出处
《国际内分泌代谢杂志》
北大核心
2014年第1期67-70,共4页
International Journal of Endocrinology and Metabolism
基金
国家自然科学基金资助项目（81070695,81270960）
教育部“新世纪优秀人才支持计划”（NCET-11-0507）
